Aktienanalyse zu DiaMedica Therapeutics Inc (DMAC)DMACDiaMedica Therapeutics Inc

DiaMedica Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on improving the lives of people suffering from preeclampsia (PE) and acute ischemic stroke (AIS). The Company’s lead candidate, DM199, is the first pharmaceutically active recombinant (synthetic) form of the KLK1 protein, an established therapeutic modality in Asia for the treatment of pre-eclampsia, acute ischemic stroke and other vascular diseases. DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1 (rhKLK1) in clinical development for preeclampsia and acute ischemic stroke. KLK1 is a serine protease enzyme that is involved in the regulation of diverse physiological processes via a molecular mechanism that increases the production of nitric oxide, prostacyclin and endothelium-derived hyperpolarizing factors. In the treatment of preeclampsia, DM199 is intended to lower blood pressure, enhance endothelial health and improve perfusion to maternal organs and the placenta. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

DiaMedica Therapeutics Inc (DMAC) is currently priced at $7.57, which is near its 200-day simple moving average of $7.081, indicating potential support. However, the stock has a low RSI of 37.218, suggesting it is oversold, yet it has also experienced a significant 9.12% drop over the past five days. The company's forward P/E ratio is 0, indicating no earnings expected in the near term, which raises concerns about its profitability. The main risk is the widening net loss reported for Q2 2026, which reached $10.1 million, up from $7.7 million the previous year, highlighting ongoing financial challenges.